Alessandro Pizzocaro

Alessandro Pizzocaro

Auto-generated profile, based on publicly available information

Alessandro Pizzocaro

Endocrinology, Diabetology and Medical Andrology Unit, IRCCS Humanitas Research Hospital, Milan, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2022 in Andrology
Verified
Journal Article
Closed access
GCGiovanni Corona
Giovanni Corona
WVWalter Vena
Walter Vena
APAlessandro Pizzocaro
Alessandro Pizzocaro
LVLinda Vignozzi
Linda Vignozzi
ASAlessandra Sforza
Alessandra Sforza
MMMario Maggi
Mario Maggi

12 August 2021 in Cells
Verified
Journal Article
Open access
PDF file
Daniele SantiDaniele Santi
Daniele Santi
GSGiorgia Spaggiari
Giorgia Spaggiari
WVWalter Vena
Walter Vena
APAlessandro Pizzocaro
Alessandro Pizzocaro
MMMario Maggi
Mario Maggi
GCGiovanni Corona
Giovanni Corona
Background: Hypogonadism is a common comorbidity in human immunodeficiency virus (HIV)-infected men, although the real prevalence is difficult to be estimated. Moreover, in HIV settings, the efficacy of exogenous testosterone (Te) administration at improving body composition remains unclear. Aim of the study: This review has a double aim. First, to estimate the prevalence of pituitary–testis axis abnormality in HIV-infected patients compared to uninfected subjects. Second, to evaluate the effect of androgen administration on body composition in HIV-infected men. Materials and Methods: A systematic review of the literature and meta-analysis was carried out. Two separated literature searches were performed, the first to evaluate the prevalence of Te deficiency in HIV-infected men and the second one to evaluate effects of androgen administration on body composition. Results: The overall prevalence of Te deficiency in HIV-infected men was calculated from 41 studies, showing a 26% prevalence, which was even higher when free T (fT) levels, more than total T, were considered. Indeed, TT serum levels were similar between HIV patients and controls, although higher SHBG and lower fT were detected in HIV populations. When HIV-infected men were treated with exogenous Te, a significant increase in body weight, lean body mass and fat free mass was detected. Conclusion: The systematic review confirms the high prevalence of Te deficiency in HIV-infected men, particularly when fT has been considered. Moreover, chronic androgen supplementation improves body composition, affecting the lean mass compartment. However, considering the general frailty of HIV patients, a tailored indication for Te therapy should be advocated.

28 August 2022 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
WVW. Vena
W. Vena
FCF. Carrone
F. Carrone
ADA. Delbarba
A. Delbarba
OAO. Akpojiyovbi
O. Akpojiyovbi
LPL. C. Pezzaioli
L. C. Pezzaioli
AFA. Ferlin
A. Ferlin

18 November 2021 in Journal of Endocrinological Investigation
Verified
Journal Article
Open access
PDF file
WVW. Vena
W. Vena
APA. Pizzocaro
A. Pizzocaro
GMG. Maida
G. Maida
MAM. Amer
M. Amer
Antonio VozaAntonio Voza
Antonio Voza
Gherardo MazziottiGherardo Mazziotti
Gherardo Mazziotti
Purpose Hypogonadism was described in high number of male subjects with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this study, we investigated whether low testosterone (T) values may influence the clinical presentation and outcome of SARS-CoV-2-related pneumonia in a large population of adult males with coronavirus disease 19 (COVID-19). Methods Two hundred twenty one adult males hospitalized for COVID-19 at the IRCCS Humanitas Research Hospital, Rozzano-Milan (Italy) were consecutively evaluated for arterial partial pressure oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio, serum T and inflammatory parameters at study entry, need of ventilation during hospital stay and in-hospital mortality. Results Subjects low T values (< 8 nmol/L; 176 cases) were significantly older (P = 0.001) and had higher serum interleukin-6 (P = 0.001), C-reactive protein (P < 0.001), lactate dehydrogenase (P < 0.001), ferritin (P = 0.012), lower P/F ratio (P = 0.001), increased prevalence of low T3 syndrome (P = 0.041), acute respiratory insufficiency (P < 0.001), more frequently need of ventilation (P < 0.001) and higher mortality rate (P = 0.009) compared to subjects with higher T values. In the multivariable regression analyses, T values maintained significant associations with acute respiratory insufficiency (odds ratio [OR] 0.85, 95% confidence interval [CI] 0.79–0.94; P < 0.001 and in-hospital mortality (OR 0.80, 95% CI 0.69–0.95; P = 0.009), independently of age, comorbidities, thyroid function and inflammation. Conclusion Low T levels values are associated with unfavorable outcome of COVID-19. Prospective studies are needed to evaluate the long-term outcomes of hypogonadism related to COVID-19 and the clinical impact of T replacement during and after acute illness.

20 December 2016 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
LCL. Cozzaglio
L. Cozzaglio
APA. Pizzocaro
A. Pizzocaro
FCF. Cancellieri
F. Cancellieri

25 May 2026 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Open access
ADandrea delbarba
andrea delbarba
MAMyriam Amer
Myriam Amer
WVWalter Vena
Walter Vena
BCBiagio Cangiano
Biagio Cangiano
EFEmanuele Ferrante
Emanuele Ferrante
MBMarco Bonomi
Marco Bonomi
Male hypogonadism is associated with significant alterations in body composition, including reduced lean body mass (LBM), increased fat body mass (FBM), particularly visceral adiposity, and impaired muscle function, contributing to frailty and cardiometabolic risk. These changes reflect the disruption of a complex endocrine crosstalk among bone, muscle, and adipose tissue, mediated by cytokines such as osteokines, myokines, and adipokines. This dysregulation promotes the development of osteosarcopenic obesity, a condition characterized by the coexistence of low bone mass, sarcopenia, and excess adiposity. Testosterone (T) plays a central role in maintaining body composition by stimulating muscle protein synthesis, inhibiting adipogenesis, and preserving bone health. Its deficiency, irrespective of etiology, leads to rapid impairment of anabolic pathways, resulting in decreased lean mass and increased fat accumulation. Evidence from clinical and experimental models demonstrates that these alterations are partially reversible with T replacement therapy (TRT), although variability exists depending on the underlying cause of hypogonadism. Dual-energy X-ray absorptiometry (DXA) represents the gold standard for assessing bone mineral density (BMD) and a key tool for evaluating body composition through a three-compartment model. It allows precise quantification of fat and lean mass, as well as their regional distribution, with minimal radiation exposure. In this review, we provide a comprehensive and clinically oriented overview of body composition alterations in male hypogonadism, focusing on underlying pathophysiological mechanisms and the practical application of DXA across different clinical scenarios. We discuss evidence from conditions such as Klinefelter syndrome, Kallmann syndrome, androgen deprivation therapy, HIV infection, and transgender care, aiming to offer a pragmatic framework for integrating body composition assessment into routine practice and improving patient management.